Ken Griffin Myovant Sciences Ltd. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$24.03 - $27.02 $2.61 Million - $2.94 Million
-108,700 Reduced 76.23%
33,900 $913,000
Q3 2022

Nov 14, 2022
BUY
$11.6 - $20.44 $838,680 - $1.48 Million
72,300 Added 102.84%
142,600 $2.56 Million

Others Institutions Holding MYOV

# of Institutions
6
Shares Held
61.3K
Call Options Held
0
Put Options Held
0
View Full List

About Myovant Sciences Ltd.

MYOV Quotes by TradingView
  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email